CD25mAb及联合供体脾细胞诱导心脏移植免疫低反应性

The Induction of Hyporesponse to Heart Allografts by Vein Injecting of CD25mAb or Associated with Donor Splenocytes

目的观察静脉应用CD25mAb及联合应用供体脾细胞对移植心脏生存时间的影响。方法建立大鼠异位心脏移植模型,术中应用CD25mAb及联合应用供体脾细胞。术后通过腹壁触诊判断移植心脏存活情况。结果CD25mAb组移植心脏生存时间为12.10±4.04天,与未用药组(8.5±2.42天)相比差异有显著性意义(P<0.05)。CD25mAb+供体脾细胞组移植心脏生存时间为12.80±3.61天,与单独应用CD25mAb组相比没有明显差异(P>0.05),但比单独用脾细胞组(8.40±3.50天,P<0.05)和未用药组有明显延长(P<0.05)。结论静脉应用CD25mAb及联合应用供体脾细胞均可以延长移植心脏生存时间。

Objective To observe the heart aUografts survival time after administration of immunosuppressive agents CD25mAb or associated with donor splenocytes in a single dose on the time of operation. Methods A simplified heterotopic rat heart transplantation model was established and the CD25mAb （1mg/kg） were injected through vein or associated with donor splenocytes （1× 10^9 cells/100g）. The grafts survival was observed by palpating over the abdominal wall postoperation. Results In using CD25mAb group, the average of the survival of heart allograft was 12.10 ± 4.04 days, which had a significant difference compared with those of the no therapy group （8.5 ± 2.42 days, P〈0.05）. In using CD25mAb＋donor splenocytes group, the average survival of heart allografts is 12.80 ±3.61 days, which had no significant difference with those of using CD25mAb alone （P〉0.05）, and much longer than those of using donor splenocytes group （8.40 ±3.50 days, P〈0.05） and no therapy group （P〈0.05）. Conclusion The findings demonstrate that a single injection of CD25mAb or associated with donor splenocytes can induce stable longterm acceptance of heart allografts.